Company to Also Host Fireside Chat at the 24th Annual ICR Conference on January 10, 2022
NEW YORK and LEAMINGTON, Ontario, Dec. 20, 2021 (GLOBE NEWSWIRE) — Tilray, Inc. (“Tilray” or the “Company”) (NASDAQ: TLRY; TSX: TLRY) announced that the Company will release financial results for its second quarter fiscal 2022 ended November 30, 2021 before financial markets open on January 10, 2022.
Tilray executives will host a conference call and live audio webcast to discuss these results at 8:30 am Eastern Time, details of which are provided below.
Live Conference Call and Audio Webcast:
Date/Time: Monday, January 10, 2022 at 8:30 am Eastern Time.
Call-in Number: (877) 407-0792 from Canada and the U.S. or (201) 689-8263 from international locations. Please dial in at least 10 minutes prior to the start time.
A telephone replay will be available approximately two hours after the call concludes through January 26, 2022. To access the recording dial (844)-512-2921 and use the passcode 13725661.
Live Audio Webcast and Replay:
There will be a simultaneous, live webcast available on the Investors section of Tilray’s website at www.tilray.com. The webcast will also be archived.
Additionally, Tilray shareholders will be able to submit and upvote questions for the upcoming conference call to the executive team via shareholder Q&A platform Say Technologies.
To submit questions ahead of the conference call, please visit the Say platform (https://app.saytechnologies.com/tilray-2022-q2?filter=all&sort=num_shares). Tilray shareholders and brokers with Say can participate directly in their investing app or broker website. The Q&A platform for Tilray’s upcoming conference call on January 10, 2022, will remain open until 24 hours beforehand.
ICR Conference Participation
Irwin D Simon, Chairman and Chief Executive Officer, and Carl Merton, Chief Financial Officer, will also participate in a separate fireside chat discussion and hold investor meetings at the 24th Annual ICR Conference. Tilray’s fireside chat discussion will be held on Monday, January 10, 2022 at 1:30 pm Eastern Time.
The live audio webcast will be accessible in the Events & Presentation section on the Company’s Investor Relations website at https://ir.tilray.com/events-and-presentations/events. An archived replay of the webcast will also be available shortly after the live event has concluded.
About Tilray
Tilray Inc. is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.
For more information about Tilray, Inc., visit: http://www.Tilray.com
Contacts
For media inquiries, please contact:
Berrin Noorata
news@tilray.com
For investor inquiries, please contact:
Raphael Gross 203-682-8253
Raphael.Gross@icrinc.com
HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…
This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…
Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…
SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…